Sagimet announced positive 52-week ASC40-304 open-label extension results for denifanstat in acne, showing durable efficacy with 57% IGA success and around 72% total lesion reduction. Safety remained favorable with no drug-related discontinuations, though mild dryness-related AEs occurred. The U.S. AURORA Phase 3 trial screening begins October 2026, signaling near-term catalysts and potential first-in-class oral acne therapy if approved.
Sagimet Biosciences has priced an underwritten offering at $6.00 per share, expected to raise about $175 million. The proceeds will significantly support the company's ongoing clinical trials, particularly for its acne treatment drug, which may enhance its market position and drive future stock appreciation.
